Bio-Techne (TECH) Long-Term Deferred Tax (2010 - 2025)

Bio-Techne (TECH) recorded quarterly Long-Term Deferred Tax of $10.3 million in Q2 2025, up 1812.24% quarter-over-quarter from $539000.0 in Q1 2011.

Bio-Techne (TECH) Long-Term Deferred Tax (2010 - 2025) Analysis & Trends

Bio-Techne's Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $10.3 million for Q2 2025.

In Q2 2025, Long-Term Deferred Tax changed N/A year-over-year to $10.3 million; the TTM figure through Jun 2025 stood at $10.3 million (changed N/A YoY), while the FY2025 annual figure was $10.3 million, changed N/A from the prior year.
Long-Term Deferred Tax was $10.3 million for Q2 2025 at Bio-Techne, up from $539000.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $10.3 million in Q2 2025 to a low of $10.3 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Bio-Techne	9.04 Bn	8.83 Bn	208.29 Mn

Download Data